Status:
TERMINATED
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection
Lead Sponsor:
Centre Hospitalier de PAU
Conditions:
COVID-19 Infection
Encephalitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature...
Detailed Description
In animals, coronavirus infection is commonly associated with CNS involvement: epilepsy and ataxia are observed during Feline Infectious Peritonitis (FIP) and virus is recovered in CSF, CNS is involv...
Eligibility Criteria
Inclusion
- Infection with Covid-19 (proven or probable) AND
- possible encephalitis (at least confusion, epilepsy) OR
- clinical severity requiring invasive ventilation.
Exclusion
- brain stroke
- minor CNS dysfunction (isolated smell loss or headache),
- absence of Covid infection.
Key Trial Info
Start Date :
May 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 25 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04361344
Start Date
May 19 2020
End Date
October 25 2020
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CH de Pau
Pau, France, 64046